BioCentury | Feb 17, 2017
Finance

Tokyo connection

...capital allocation to university opportunities." Its sole investment is French Orphan play InFlectis BioScience S.A.S. Remiges co-led InFlectis'...
BioCentury | Jun 13, 2016
Finance

Small price of progress

...Although European biotechs have long had a problem making progress on small series A rounds, InFlectis BioScience S.A.S....
...and Participations Besançon. The investors have an option to increase the round by €1.5 million. InFlectis...
...Remiges' Taro Inaba. "We expect a significant up-round in the future series B." Guédat said InFlectis...
BioCentury | Jun 6, 2016
Financial News

InFlectis completes venture financing

...million ($5 million) Investors: CM-CIC Capital Innovation; Remiges Ventures; GO Capital Fund; Participations Besancon Note: InFlectis...
BioCentury | May 11, 2015
Emerging Company Profile

Preventing accumulation

...up-regulates chaperones that facilitate protein folding, and one that up-regulates proteases to degrade misfolded proteins. InFlectis'...
...phosphatase that turns off the protein responsible for activating the pathway. By blocking this phosphatase, InFlectis...
...expressed only in stressed cells, so IFB-088 does not affect protein synthesis in normal cells. InFlectis...
BioCentury | Apr 23, 2015
Distillery Therapeutics

Therapeutics: Protein phosphatase 1 regulatory inhibitor subunit 15A (PPP1R15A; PEG-3); eukaryotic translation initiation factor 2 (eIF2) subunit 1α (eIF-2α; EI

...demyelination. Next steps include identifying additional diseases that could be treated with the PPP1R15A inhibitor. InFlectis...
BioCentury | Mar 16, 2015
Company News

Valneva, InFlectis deal

...Valneva granted InFlectis exclusive, worldwide rights to the protein-protein interaction drug discovery platform 3D-Screen for all...
...rights to the protein-protein interaction drug discovery platform 3D-Screen for all indications except HCV infection. InFlectis...
...for infectious disease drug discovery. Financial terms are not disclosed. Valneva SE (Euronext:VLA;VSE:VLA), Lyon, France InFlectis...
Items per page:
1 - 6 of 6
BioCentury | Feb 17, 2017
Finance

Tokyo connection

...capital allocation to university opportunities." Its sole investment is French Orphan play InFlectis BioScience S.A.S. Remiges co-led InFlectis'...
BioCentury | Jun 13, 2016
Finance

Small price of progress

...Although European biotechs have long had a problem making progress on small series A rounds, InFlectis BioScience S.A.S....
...and Participations Besançon. The investors have an option to increase the round by €1.5 million. InFlectis...
...Remiges' Taro Inaba. "We expect a significant up-round in the future series B." Guédat said InFlectis...
BioCentury | Jun 6, 2016
Financial News

InFlectis completes venture financing

...million ($5 million) Investors: CM-CIC Capital Innovation; Remiges Ventures; GO Capital Fund; Participations Besancon Note: InFlectis...
BioCentury | May 11, 2015
Emerging Company Profile

Preventing accumulation

...up-regulates chaperones that facilitate protein folding, and one that up-regulates proteases to degrade misfolded proteins. InFlectis'...
...phosphatase that turns off the protein responsible for activating the pathway. By blocking this phosphatase, InFlectis...
...expressed only in stressed cells, so IFB-088 does not affect protein synthesis in normal cells. InFlectis...
BioCentury | Apr 23, 2015
Distillery Therapeutics

Therapeutics: Protein phosphatase 1 regulatory inhibitor subunit 15A (PPP1R15A; PEG-3); eukaryotic translation initiation factor 2 (eIF2) subunit 1α (eIF-2α; EI

...demyelination. Next steps include identifying additional diseases that could be treated with the PPP1R15A inhibitor. InFlectis...
BioCentury | Mar 16, 2015
Company News

Valneva, InFlectis deal

...Valneva granted InFlectis exclusive, worldwide rights to the protein-protein interaction drug discovery platform 3D-Screen for all...
...rights to the protein-protein interaction drug discovery platform 3D-Screen for all indications except HCV infection. InFlectis...
...for infectious disease drug discovery. Financial terms are not disclosed. Valneva SE (Euronext:VLA;VSE:VLA), Lyon, France InFlectis...
Items per page:
1 - 6 of 6